Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
The biotech company’s merger with Ikena Oncology will bring in $175 million in fresh funds, including $75 million from an oversubscribed private placement Key Takeaways: Inmagene Bio plans to merge…
